Lege Artis Medicinae

[Cardiovascular diseaes and the kidney]

PRÉDA István

JANUARY 20, 2003

Lege Artis Medicinae - 2003;13(01)

[From pathophysiological point of view, the kidney is an integral part of the cardiovascular system. Renal diseases adversely affect the cardiac functions, and disturbances of the cardiovascular system affect adversely renal functions, causing either the decrease of left ventricular functions or manifesting in overt chronic heart failure. Regarding the cardiac manifestations of renal diseases, characteristic features are the symptoms of left ventricular volume and pressure overload, the metabolic effects of the ”uremic toxins” and the frequent infections associated with dialysis and compromised immunologic state, the secunder hyperparathyreosis, as well as the associated conditions like hypertension, diabetes mellitus and coronary atherosclerosis. All these can be the explanation for the frequent cardiovascular death of chronic kidney disease patients. It also stresses the outstanding importance of the decrease of cardiovascular hazard of chronic renal disease patients. The strategy should comprise of an adequate antihypertensive treatment (ACE-inhibitor, AT-II blocking and calcium antagonist), strong antidiabetic control of diabetic patients and the adequate treatment of dyslipidaemia (if exists), as well as antithrombotic aspirin treatment.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Evidence-based practice guidelines for nursing and rehabilitation of stroke patients]

BALOGH Zoltán

[Stroke is a common problem, being the third most frequent cause of death in the United Kingdom and Hungary, accounting for about 20% of bed occupancy. It is also an important cause of morbidity and disability mainly for those aged over 65. As a result, stroke care constitutes as an important part of health services use. Home care services working in the field of stroke rehabilitation have not used a unified evidence-based approach and well-described professional principles and protocols. There was little cooperation between the teams working in the institutional rehabilitation and home care rehabilitation services. No agreed rehabilitation processes, and standardised scales and documentation, showing the change of quality of life, were in use. There were no quality indicators and efficiency measures of nursing and no provision of services either. The Hungarian Nursing Association played a pioneering role in the introduction and dissemination of Evidence Based Nursing in Hungary and in adopting it into routine clinical practice. The successful implementation of the Association's project could be a good example for another field of care and nursing in Hungary and other countries in Europe. Our projects are supported by the Department For International Development (UK) in the framework of the TUDOR project. The Hungarian Nursing Association (HNA) developed a postgraduate training programme entitled "Evidence based nursing in practice". The participants were required to be members of the HNA, have a degree in the field of nursing (nurse teacher, degree nurse, nurse director). Members of the target group were all working in the field of stroke rehabilitation at hospitals or out-patient clinics and home nursing. The Hungarian Nursing Association's professional group developed an evidence based practice guideline for rehabilitation of stroke patients, which was published in the Bulletin of the Ministry of Health (11/2002, 23rd May, 2002). These evidence-based stroke rehabilitation guidelines focused on bladder management, position therapy and patient information.]

Lege Artis Medicinae

[4th International Congress of Pathophysiology]

ROSIVALL László, MONOS Emil

Lege Artis Medicinae

[Errors and mistakes in laboratory medicine]

ENDRŐCZI Elemér

[The unacceptable results of laboratory testing derive from the insufficient preanalytical, analytical and postanalytical processes. In addition to the analytical errors, there are inappropriate testing orders which reflect the failures of diagnostic strategy, and either result in excess testing orders without additional new informations, or in the lack of testing order that would be necessary for efficiency of patient's care. An increasing number of study demonstrate that in majority of cases the cause of erroneous results can be traced back to mistakes in the preanalytical phase (preparation of patient, sample collection). The total quality of the diagnostic strategy depends both on the compliance of tests according to the health condition of patient and the quality performance of laboratory processes. The elimination of the preanalytical errors and the formulation of proper diagnostic strategy requires a close cooperation between physicians and the diagnostic workplaces as well as the application of multidisciplinary guidelines which specify the quality requirements of the whole diagnostic process. Such guidelines are not prepared for specific professional activities and do not replace lower-level professional standards (e.g. for test procedures). Based on evidence-based medicine and the recommendations of international experts such guidelines should cover all elements of quality assurance necessary to achieve efficient diagnostic strategy and testing. There is little doubt that such recommendations will also be useful for rational financing of the health care system.]

Lege Artis Medicinae

[Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer]

REINDL Ildikó

Lege Artis Medicinae

[The efficacy, tolerability and gastrointestinal safety of celecoxib in osteoarthritis and rheumatoid arthritis]

SZEKANECZ Zoltán

All articles in the issue

Related contents

Hypertension and nephrology

[Diuretikumok hypertoniában - 2010]

BARNA István

[Diuretics (especially thiazide derivatives and indapamide that also has vasodilator efficacy) are considered as first line treatment in hypertension. They are particularly favourable in the treatment of overweight, elderly, isolated systolic hypertensive patients suffering from type 2 diabetes and metabolic syndrome or in mild renal and cardiac insufficiency. They can be ideally combined with other antihypertensive agents (primarily with angiotensin-converting enzyme inhibitors, angiotensin receptor blocking agents és béta-blockers). If hypertension is associated with left ventricular hypertrophy or stroke indapamide is the appropriate choice. In case of left ventricular dysfunction and heart failure thiazide and/or furosemide is the adequate option. Low dose diuretics have no clinically relevant side effects and reduce cardiac mortality to the same extent as other pharmaceutical interventions.]

Lege Artis Medicinae

[RECOGNITION AND MANAGEMENT OF ACUTE HEART FAILURE]

KARLÓCAI Kristóf

[Acute heart failure may develop in previously healthy hearts. Nevertheless, structural abnormalities can facilitate its development and also, chronic heart failure can progress into acute stage. Considering the total cost of care in the patient's life, this is the most expensive heart disease. The clinical signs and physical abnormalities are usually of diagnostic power, however, instrumental investigations are necessary to recognize complications and to guide therapy. Patients should be monitored in well equipped coronary care units. Therapy consists of medications, coronary revascularization and use of mechanical assist devices.]

Lege Artis Medicinae

[NON-PHARMACOLOGICAL TREATMENT OF CHRONIC HEART FAILURE]

MERKELY Béla, RÓKA Attila

[Heart failure has a poor prognosis despite the advances in pharmacological treatment. The utilization of non-pharmacological treatment with appropriate indications significantly improves the quality of life and life expectancy of these patients. Cardiac resynchronization therapy with biventricular pacemaker has a clinically proven efficacy in the treatment of heart failure associated with intraventricular dyssynchrony. Implantable cardioverter- defibrillators decrease the mortality from sudden cardiac death. Heart transplantation is needed in cases refractory to therapy. There are several other non-pharmacological treatment approaches, including mechanical circulatory assist devices, total artificial heart and ultrafiltration, whose routine application is not recommended due to limited clinical experience, but the initial results are promising.]

Lege Artis Medicinae

[POST-INFARCTION CARDIAC FAILURE]

TOMCSÁNYI János

[Recent advances in the care of acute myocardial infarction have resulted in more patients surviving myocardial infarction than earlier. However, heart failure is a common complication in these patients, which in turn is associated with substantial mortality, primarily due to a remodelling of the left ventricle that already starts in an early stage of the myocardial infarction. The aim of this review article is to present the pathomechanism of this remodelling and to discuss related therapeutic options. Current guidelines recommend the use of an angiotensin- converting enzyme inhibitor combined with or followed by an angiotensin receptor blocker, a beta-blocker, and an aldosterone antagonist in post-infarction patients with concomitant heart failure.]

Hypertension and nephrology

[ACEi or ARB? What are the results of the comparative analysis?]

BENCZÚR Béla

[Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) are treatment options for patients with cardiovascular disease (CVD) or those with cardiovascular risk factors. The comparative efficacy and safety of ACEis and ARBs have been much debated. To compare the benefits of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) in patients without heart failure a metaanalysis was carried out based on 254.301 subjects of 106 randomised trials. Meta-analysis included randomized trials of ACEis and ARBs compared with placebo or active controls and corroborated with head-to-head trials of ARBs vs ACEis. According to placebo controlled studies ACEis but not ARBs reduced all-cause mortality, cardiovascular mortality and MI. It seems that ACEis are more effective than ARBs. But this is only true if we take into account the trials before 2000. The analysis restricted to trials published after 2000 revealed similar outcomes with ACEis vs placebo and ARBs vs placebo. Head-to-head comparison trials of ARBs vs ACEis exhibited no difference in outcomes. The underlying causes and details are explained in this review.]